Lowest Price Guaranteed From USD 5,899
Published
January 2021
Pages
1060
View Count
49784
.PNG) |
 |
 |
 |
 |
.PNG) |
 |
.PNG) |
 |
.PNG) |
.PNG) |
.PNG) |
 |
.PNG) |
.PNG) |
.PNG) |
According to the World Health Organization (WHO), cancer is considered to be among the second leading causes of mortality worldwide, accounting for an estimated 10 million deaths annually. In fact, the global cancer burden is anticipated to increase by 70% in the next 20 years, exerting tremendous physical, emotional and financial strain on individuals, families, communities and health systems. Although efforts are being made to develop safe and effective drugs for the treatment of different types of cancer, there is still a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition. Amidst the current initiatives to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option owing to their capability to eradicate tumor cells from the body with minimal treatment-related side effects. These adoptive T-cell therapies (ACT) are based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. A number of chimeric antigen receptor T-cell (CAR-T) therapies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences) and TECARTUS™ (Gilead Sciences), have already been approved in the recent years validating the potential of such ACTs in cancer treatment. In addition to the industry stakeholders, more than 300 academic and research institutes, till date, have made significant contributions to this field, mostly by convening the initial research on potential therapy candidates. Prominent scientists, acting as key opinion leaders, are leading the clinical development efforts of more than 975 T-cell therapy candidates for the treatment of various oncological and non-oncological disorders. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace.
It is also worth highlighting that capital investments worth over USD 17 billion have been made by various private and public sector investors during the last five years to fund the product development activity. In addition, there have been close to 350 recently reported instances of collaborations between industry / academic stakeholders to advance the development of various pipeline candidates. The ongoing research activity in this field has led to the discovery of several disease-specific targets, such as CD19, BCMA, CD22, CD20 and meso. Driven by the availability of innovative technology platforms, lucrative funding and encouraging clinical trial results, the T-cell immunotherapies market is poised for success in the long-run as multiple product candidates are expected to be approved over the coming decade.
The “Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (5th Edition) by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2020-2030” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2021-2030. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.
Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.
Chapter 4 provides insights on the popularity of T-cell immunotherapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
Chapter 5 includes detailed assessment on more than 975 T-cell immunotherapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of product (CAR-T, TCR and TIL), type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), target therapeutic indication (non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma, brain cancer, acute myeloid leukemia, melanoma, lung cancer, ovarian cancer, liver cancer, pancreatic cancer, chronic lymphocytic leukemia, stomach cancer, breast cancer, sarcoma, mantle cell lymphoma, mesothelioma, colorectal cancer, bladder cancer and others), key target antigen (CD19, BCMA, CD22, CD20, Meso, GD2, CD38, CD123, CD30, HER2, GPC3, CD33 and CD13), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) and an insightful logo landscape, highlighting product developers in North America, Europe and the Asia Pacific.
Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T and TCR therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapies (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector (lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatory domain used.
Chapter 7 presents an analysis of the CAR-T clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.
Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
Chapter 9 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
Chapter 10 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
Chapter 11 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the T-cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.
Chapter 12 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
Chapter 13 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.
Chapter 14 provides details on the various investments and grants that have been awarded to players focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
Chapter 15 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.
Chapter 16 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.
Chapter 17 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.
Chapter 18 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others) and [D] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).
Chapter 19 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.
Chapter 20 includes brief company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 22 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital), Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) and Patrick Dougherty (SVP, Strategy, Planning and Operations, Windmil Therapeutics)
Chapter 23 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 24 is an appendix, which contains the list of companies and organizations mentioned in the report.
1 .PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. History of Development
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR for Therapy
3.8.4. Differences between CAR-T and TCR-based Therapies
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. History of Development
3.9.2. Development of TILs for Therapy
3.10. Key Challenges and Roadblocks
3.11. Concluding Remarks
4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. T-Cell Immunotherapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: Overall Market Overview
5.2.1. Analysis by Type of Product
5.3. CAR-T Cell Therapies: Overall Market Overview
5.3.1. Analysis by Type of Developer
5.3.2. Analysis by Phase of Development
5.3.3. Analysis by Therapeutic Area
5.3.4. Analysis by Popular Target Indications
5.3.5. Analysis by Popular Target Antigens
5.3.6. Analysis by Source of T-Cells
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Dose Frequency
5.3.9. Analysis by Patient Segment
5.3.10. Analysis by Type of Therapy
5.3.11. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development
5.3.12. Key Non-Industry Players: Analysis by Number of CAR-T Cell Therapies in Clinical Development
5.4. TCR-based Therapies: Overall Market Overview
5.4.1. Analysis by Type of Developer
5.4.2. Analysis by Phase of Development
5.4.3. Analysis by Therapeutic Area
5.4.4. Analysis by Popular Target Indications
5.4.5. Analysis by Popular Target Antigens
5.4.6. Analysis by Source of T-Cells
5.4.7. Analysis by Route of Administration
5.4.8. Analysis by Dose Frequency
5.4.9. Analysis by Patient Segment
5.4.10. Analysis by Type of Therapy
5.4.11. Key Industry Players: Analysis by Number of TCR-based Therapies in Development
5.4.12. Key Non-Industry Players: Analysis by Number of TCR-based Therapies in Clinical Development
5.5. TIL-based Therapies: Overall Market Overview
5.5.1. Analysis by Type of Developer
5.5.2. Analysis by Phase of Development
5.5.3. Analysis by Therapeutic Area
5.5.4. Analysis by Popular Target Indications
5.5.5. Analysis by Source of T-Cells
5.5.6. Analysis by Dose Frequency
5.5.7. Analysis by Patient Segment
5.5.8. Analysis by Type of Therapy
5.5.9. Key Industry Players: Analysis by Number of TIL-based Therapies in Development
5.5.10. Key Non-Industry Players: Analysis by Number of TIL-based Therapies in Development
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Hematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Immunotherapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Immunotherapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Immunotherapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Immunotherapies
6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Immunotherapies
6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Immunotherapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Immunotherapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Immunotherapies
6.3. T-Cell Immunotherapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Key Opinion Leaders
6.3.2. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.3.3. TCR-based Therapies: Key Opinion Leaders
6.3.4. Most Prominent Key Opinion Leaders
6.3.5. TIL-based therapies: Key Opinion Leaders
6.3.6. TIL-based Therapies: Most Prominent Key Opinion Leaders
6.4. T-Cell Immunotherapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China
8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.1.1. History of Development
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing
8.3. Yescarta / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.1.1. History of Development
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.4. Tecartus / Brexucabtagene Autoleucel (Kite Pharma)
8.4.1. Therapy Overview
8.4.2. Current Development Status
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen, Price and Manufacturing
8.5. JCAR (Juno Therapeutics (a Bristol Myers Squibb Company))
8.5.1. Therapy Overview
8.5.1.1. CAR-T Design
8.5.2. Current Development Status
8.5.3. Key Clinical Results
8.5.3.1. JCAR014
8.5.3.2. JCAR017
8.5.3.3. JCAR018
8.5.3.4. JCARH125
8.5.4. Dosage Regimen and Manufacturing
8.6. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol-Myers Squibb)
8.6.1. Therapy Overview
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Nanjing Legend Biotech / Janssen Biotech)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing
8.9. Next Generation CAR-T Cell therapies (Autolus)
8.9.1. Therapy Overview
8.9.2. Current Development Status
8.9.3. Key Clinical Trial Results
8.9.3.1. AUTO1
8.9.3.2. AUTO3
8.9.4. Dosage Regimen and Manufacturing
8.10. CAR-T Cell Therapies (Sinobioway Cell Therapy)
8.10.1. Therapy Overview
8.10.2. Current Development Status
8.10.3. Dosage Regimen and Manufacturing
9. TCR-BASED THERAPY PROFILES
9.1. Chapter Overview
9.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
9.2.1. Therapy Overview
9.2.1.1. SPEAR T-Cells Technology Platform
9.2.1.2. Letetresgene Autoleucel / GSK3377794 / NY-ESO SPEAR T-Cell
9.2.1.3. ADP-A2M10 (MAGE-A10) SPEAR T-Cell Therapy
9.2.1.4. ADP-A2AFP SPEAR T-Cell Therapy
9.2.1.5. ADP-A2M4 (MAGE-A4) SPEAR T-Cell Therapy
9.2.2. Current Development Status
9.2.3. Key Clinical Trial Results
9.2.4. Dosage Regimen And Manufacturing
9.3. IMCgp100 (Immunocore)
9.3.1. Therapy Overview
9.3.2. Current Development Status
9.3.3. Key Clinical Trial Results
9.3.4. Dosage Regimen and Manufacturing
9.4. ALT-801 (Altor BioScience)
9.4.1. Therapy Overview
9.4.1.1. History of Development
9.4.2. Current Development Status
9.4.3. Key Clinical Trial Results
9.4.4. Dosage Regimen
9.4.5. Patent Portfolio
9.5. JTCR016 (Juno Therapeutics (a Bristol Myers Squibb Company)))
9.5.1. Therapy Overview
9.5.2. Current Development Status
9.5.3. Key Clinical Trial Results
9.5.4. Dosage Regimen and Manufacturing
9.6. CMD-602 / WT1 TCR Therapy (Kuur Therapeutics)
9.6.1. Therapy Overview
9.6.1.1. History of Development
9.6.2. Current Development Status
9.6.3. Key Clinical Trial Results
9.6.4. Dosage Regimen and Manufacturing
9.7. TBI-1301 (Takara Bio)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen And Manufacturing
9.8. MDG1011 (Medigene)
9.8.1. Therapy Overview
9.8.2. Current Development Status
9.8.3. Key Clinical Trial Results
9.8.4. Dosage Regimen and Manufacturing
10. TIL-BASED THERAPY PROFILES
10.1. Chapter Overview
10.2. Autologous TIL Therapies (Iovance Biotherapeutics)
10.2.1. Therapy Overview
10.2.2. Current Development Status
10.2.2.1. LN-144
10.2.2.2. LN-145
10.2.3. Key Clinical Trial Results
10.2.3.1. LN-144
10.2.3.2. LN-145
10.2.4. Dosage Regimen and Manufacturing
10.2.5. Patent Portfolio
10.3. TIL (Nantes University Hospital)
10.3.1. Therapy Overview
10.3.2. Current Development Status
10.3.3. Key Clinical Trial Results
10.3.4. Dosage Regimen and Manufacturing
10.4. TIL (Netherlands Cancer Institute)
10.4.1. Therapy Overview
10.4.2. Current Development Status
10.4.3. Key Clinical Trial Results
10.4.4. Dosage Regimen and Manufacturing
11. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
11.1. Chapter Overview
11.2. Hematological Malignancies
11.2.1. Leukemia and Lymphoma
11.2.1.1. Leukemia: Introduction and Epidemiology
11.2.1.1.1. Acute Myeloid Leukemia (AML)
11.2.1.1.2. Chronic Myeloid Leukemia (CML)
11.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
11.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
11.2.1.2. Lymphoma: Introduction and Epidemiology
11.2.1.3. Current Treatment Landscape
11.2.1.3.1. Targeted Therapies
11.2.1.4. T-Cell Immunotherapy and Affiliated Research Landscape
11.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
11.2.1.4.2. TCR-based Therapies and Leukemia / Lymphoma
11.2.1.4.3. TIL-based Therapies and Leukemia
11.2.2. Multiple Myeloma
11.2.2.1. Introduction and Epidemiology
11.2.2.2. Current Treatment Landscape
11.2.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3. Solid Tumors
11.3.1. Metastatic Melanoma
11.3.1.1. Introduction and Epidemiology
11.3.1.2. Current Treatment Landscape
11.3.1.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.1.3.1. CAR-T Cell Therapies and Metastatic Melanoma
11.3.1.3.2. TCR-based Therapies and Metastatic Melanoma
11.3.1.3.3. TIL-based Therapies and Metastatic Melanoma
11.3.2. Lung Cancer
11.3.2.1. Introduction and Epidemiology
11.3.2.2. Current Treatment Landscape
11.3.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3. Pancreatic Cancer
11.3.3.1. Introduction and Epidemiology
11.3.3.2. Current Treatment Landscape
11.3.3.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3.3.1. CAR-T Cell Therapies and Pancreatic Cancer
11.3.3.3.2. TCR-based Therapies and Pancreatic Cancer
11.3.3.3.3. TIL-based Therapies and Pancreatic Cancer
11.3.4. Liver Cancer
11.3.4.1. Current Treatment Landscape
11.3.4.2. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.4.2.1. CAR-T Cell Therapies and Liver Cancer
11.3.4.2.2. TCR-based Therapies and Liver Cancer
11.3.4.2.3. TIL-based Therapies and Liver Cancer
11.3.5. Breast Cancer
11.3.5.1. Introduction and Epidemiology
11.3.5.2. Current Treatment Landscape
11.3.5.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.5.3.1. CAR-T Cell Therapies and Breast Cancer
11.3.5.3.2. TCR-based Therapies and Breast Cancer
11.3.5.3.3. TIL-based Therapies and Breast Cancer
11.3.6. Ovarian Cancer
11.3.6.1. Introduction and Epidemiology
11.3.6.2. Current Treatment Landscape
11.3.6.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.6.3.1. CAR-T Cell Therapies and Ovarian Cancer
11.3.6.3.2. TCR-based Therapies and Ovarian Cancer
11.3.6.3.3. TIL-based Therapies and Ovarian Cancer
11.3.7. Bladder Cancer
11.3.7.1. Introduction and Epidemiology
11.3.7.2. Current Treatment Landscape
11.3.7.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.8. Kidney Cancer
11.3.8.1. Introduction and Epidemiology
11.3.8.2. Current Treatment Landscape
11.3.8.3. T-Cell Immunotherapy and Affiliated Research Landscape
12. EMERGING TECHNOLOGIES
12.1. Chapter Overview
12.2. Genome Editing Technologies
12.2.1. Technology Overviews
12.2.2. Applications
12.2.3. Emerging Technology Platforms Used in T-Cell Therapies
12.2.3.1. CRISPR / Cas9 System
12.2.3.1.1. Key Components and Function
12.2.3.1.2. Mechanism of Action
12.2.3.1.3. Targeting Efficiency and Challenges
12.2.3.1.4. Next-GEN CRISPR Technology
12.2.3.1.5. Technology Providers
12.2.3.1.5.1. Editas Medicine
12.2.3.1.5.2. Intellia Therapeutics
12.2.3.1.5.3. CRISPR Therapeutics
12.2.3.1.5.4. Beam Therapeutics
12.2.3.1.5.5. Gracell Biotechnologies
12.2.3.2. TALENs
12.2.3.2.1. Key Components and Function
12.2.3.2.2. Mechanism of Action
12.2.3.2.3. Advantages and Challenges
12.2.3.2.4. Technology Providers
12.2.3.2.4.1. Cellectis
12.2.3.2.4.2. Editas Medicine
12.2.3.3. megaTAL
12.2.3.3.1. Technology Providers
12.2.3.3.1.1. bluebird bio
12.2.3.4. Zinc Finger Nuclease
12.2.3.4.1. Technology Providers
12.2.3.4.1.1. Sangamo Therapeutics
12.2.4. Competitive Analysis: Gene Editing Platforms
12.3. Designing T-Cell Therapies with Improved Characteristics
12.3.1. Technologies For Targeting Multiple Cancers
12.3.1.1. Antibody Coupled T-Cell Receptor
12.3.1.1.1. Cogent Biosciences
12.3.1.2. NKR-T Platform
12.3.1.2.1. Celyad
12.3.1.2.2. Glycostem
12.3.2. Technologies For Improved Safety
12.3.2.1. Armored CAR and EGFRt Technology
12.3.2.1.1. Juno Therapeutics
12.3.2.2. RheoSwitch Therapeutic System
12.3.2.2.1. Intrexon
12.3.2.3. Inducible Caspase 9 Safety Switch
12.3.2.3.1. Bellicum Pharmaceuticals
12.3.2.3.1.1. CaspaCIDe Technology
12.3.2.3.1.2. CIDeCAR Technology
12.3.2.3.1.3. GoCAR-T Technology
12.3.2.4. On-Off Switch, Multiple Companies
12.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
12.3.2.4.2. On-Off Switch (Theravectys)
12.3.2.5. Other Technologies to Improve CAR-T Safety
12.3.3. Allogeneic Technologies
12.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
12.3.3.2. Allogeneic Platform (Celyad)
12.3.3.3. Allogeneic Platform (Cellectis)
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Type of Partnership and Type of Product
13.3.4. Analysis by Type of Partner and Type of Product
13.3.5. Most Popular Products
13.3.6. Most Active Industry Players: Analysis by Number of Partnerships
13.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
13.3.8. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
13.3.9. Regional Analysis
13.3.10. Intercontinental and Intracontinental Agreements
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
14.3.1. Analysis by Year of Investment
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis of Amount Invested across Different Types of Therapies
14.3.5. Most Active Players: Analysis by Number of Instances
14.3.6. Analysis by Type of Investor
14.3.7. Most Active Investors: Analysis by Number of Instances
14.3.8. Regional Analysis by Amount Invested
15. OTHER T-CELL IMMUNOTHERAPIES
15.1. Chapter Overview
15.2. Other T-Cell Immunotherapies
15.2.1. Analysis by Phase of Development
15.2.2. Analysis by Target Therapeutic Area
15.2.3. Analysis by Type of T-Cells
15.2.4. Analysis by Source of T-Cells
15.3. Treg Cell Therapy
15.3.1. Caladrius Biosciences
15.3.2. TRACT Therapeutics
15.3.3. Cellenkos
15.3.4. Other Companies
15.4. T-Cell Based Vaccines
15.4.1. Immunovative Therapies
15.4.2. TVAX Biomedical
15.5. Virus-Driven T-Cell Therapies
15.5.1. Atara Biotherapeutics
15.5.2. bluebird bio
15.5.3. Kuur Therapeutics
15.5.4. Eutilex
15.5.5. Tessa Therapeutics
15.5.6. ViGenCell
15.6. Fucosylated T-Cell Therapies
15.6.1. Targazyme
15.7. PD-1 Knockout Engineered T-Cell Therapies
15.7.1. Chengdu MedGenCell
15.7.2. Anhui Kedgene Biotechnology
15.8. TAC-T Cell Therapies
15.8.1. Triumvira Immunologics
15.9. Gama Delta T-Cell Therapies
15.9.1. GammaCell Bio-Technologies
15.9.2. GammaDelta Therapeutics
15.9.3. TC Biopharm
16. CASE STUDY: CELL THERAPY MANUFACTURING
16.1. Chapter Overview
16.2. Overview to Cell Therapy Manufacturing
16.3. Cell Therapy Manufacturing Models
16.3.1. Centralized Manufacturing Model
16.3.2. Decentralized Manufacturing Model
16.4. Scalability of Cell Therapy Manufacturing Processes
16.4.1. Scale-Up
16.4.2. Scale-out
16.5. Types of Cell Therapy Manufacturers
16.6. Key Challenges Related to Manufacturing Cell Therapies
16.7. Important Factors for Cell Therapy Manufacturing
16.7.1. Characterization
16.7.2. Cost of Goods
16.8. Automation of Cell Therapy Manufacturing Processes
16.9. Cell Therapy Manufacturing Supply Chain
16.10. Companies with In-House Capabilities and Contract Manufacturers
16.11. Regulatory Landscape
17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factorss Contributing to the High Price of Cell / Gene Therapies
17.3. Pricing Models for T-Cell Immunotherapies
17.3.1. Based on Associated Costs
17.3.2. Based on Availability of Competing Products
17.3.3. Based on Patient Segment
17.3.4. Based on the Opinions of Industry Experts
17.4. Reimbursement-related Considerations For T-Cell Immunotherapies
17.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
18. MARKET SIZING AND OPPORTUNITY ANALYSIS
18.1. Chapter Overview
18.2. Scope and Limitations
18.3. Key Assumptions And Forecast Methodology
18.4. Overall T-Cell Immunotherapy Market, 2021-2030
18.4.1. T-Cell Immunotherapy Market: Distribution by Type of Therapy
18.4.2. T-Cell Immunotherapy Market: Distribution by Target Indications
18.4.3. T-Cell Immunotherapy Market: Distribution by Target Antigen
18.4.4. T-Cell Immunotherapy Market: Key Players
18.4.5. T-Cell Immunotherapy Market: Distribution by Geography
18.5. T-Cell Immunotherapy Market: Value Creation Analysis
18.6. Overall CAR-T Cell Therapies Market, 2021-2030
18.6.1. CAR-T Cell Therapies Market: Distribution by Target Indication
18.6.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
18.6.3. CAR-T Cell Therapies Market: Key Players
18.6.4. CAR-T Cell Therapies Market: Distribution by Geography
18.6.5. Product Wise Sales Forecast
18.6.5.1. Kymriah (Novartis)
18.6.5.1.1. Target Patient Population
18.6.5.1.2. Sales Forecast (USD Million)
18.6.5.1.3. Net Present Value
18.6.5.1.4. Value Creation Analysis
18.6.5.2. Yescarta (Gilead Sciences)
18.6.5.2.1. Target Patient Population
18.6.5.2.2. Sales Forecast (USD Million)
18.6.5.2.3. Net Present Value (USD Million)
18.6.5.2.4. Value Creation Analysis
18.6.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
18.6.5.3.1. Target Patient Population
18.6.5.3.2. Sales Forecast (USD Million)
18.6.5.3.3. Net Present Value (USD Million)
18.6.5.3.4. Value Creation Analysis
18.6.5.4. Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb)
18.6.5.4.1. Target Patient Population
18.6.5.4.2. Sales Forecast (USD Million)
18.6.5.4.3. Net Present Value (USD Million)
18.6.5.4.4. Value Creation Analysis
18.6.5.5. Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
18.6.5.5.1. Target Patient Population
18.6.5.5.2. Sales Forecast (USD Million)
18.6.5.5.3. Net Present Value (USD Million)
18.6.5.5.4. Value Creation Analysis
18.6.5.6. JCAR017 (Juno Therapeutics / Celgene / Wuxi AppTec)
18.6.5.6.1. Target Patient Population
18.6.5.6.2. Sales Forecast (USD Million)
18.6.5.6.3. Net Present Value (USD Million)
18.6.5.6.4. Value Creation Analysis
18.6.5.7. MB-CART19.1 (Miltenyi Biotec)
18.6.5.7.1. Target Patient Population
18.6.5.7.2. Sales Forecast (USD Million)
18.6.5.7.3. Net Present Value (USD Million)
18.6.5.7.4. Value Creation Analysis
18.6.5.8. Descartes-11 (Cartesian Therapeutics)
18.6.5.8.1. Target Patient Population
18.6.5.8.2. Sales Forecast (USD Million)
18.6.5.8.3. Net Present Value (USD Million)
18.6.5.8.4. Value Creation Analysis
18.6.5.9. CD19 CAR-T (Sinobioway Cell Therapy)
18.6.5.9.1. Target Patient Population
18.6.5.9.2. Sales Forecast (USD Million)
18.6.5.9.3. Net Present Value (USD Million)
18.6.5.9.4. Value Creation Analysis
18.6.5.10. AUTO1 (Autolus)
18.6.5.10.1. Target Patient Population
18.6.5.10.2. Sales Forecast (USD Million)
18.6.5.10.3. Net Present Value (USD Million)
18.6.5.10.4. Value Creation Analysis
18.6.5.11. AUTO3 (Autolus)
18.6.5.11.1. Target Patient Population
18.6.5.11.2. Sales Forecast (USD Million)
18.6.5.11.3. Net Present Value (USD Million)
18.6.5.11.4. Value Creation Analysis
18.6.5.12. GPC3 CAR-T (Shanghai GeneChem)
18.6.5.12.1. Target Patient Population
18.6.5.12.2. Sales Forecast (USD Million)
18.6.5.12.3. Net Present Value (USD Million)
18.6.5.12.4. Value Creation Analysis
18.6.5.13. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.13.1. Target Patient Population
18.6.5.13.2. Sales Forecast (USD Million)
18.6.5.13.3. Net Present Value (USD Million)
18.6.5.13.4. Value Creation Analysis
18.6.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.14.1. Target Patient Population
18.6.5.14.2. Sales Forecast (USD Million)
18.6.5.14.3. Net Present Value (USD Million)
18.6.5.14.4. Value Creation Analysis
18.6.5.15. CD19 CAR-T (Shanghai Bioray Laboratory)
18.6.5.15.1. Target Patient Population
18.6.5.15.2. Sales Forecast (USD Million)
18.6.5.15.3. Net Present Value (USD Million)
18.6.5.15.4. Value Creation Analysis
18.6.5.16. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.16.1. Target Patient Population
18.6.5.16.2. Sales Forecast (USD Million)
18.6.5.16.3. Net Present Value (USD Million)
18.6.5.16.4. Value Creation Analysis
18.6.5.17. PCAR-019 (PersonGen BioTherapeutics)
18.6.5.17.1. Target Patient Population
18.6.5.17.2. Sales Forecast (USD Million)
18.6.5.17.3. Net Present Value (USD Million)
18.6.5.17.4. Value Creation Analysis
18.6.5.18. TBI-1501 (Takara Bio)
18.6.5.18.1. Target Patient Population
18.6.5.18.2. Sales Forecast (USD Million)
18.6.5.18.3. Net Present Value (USD Million)
18.6.5.18.4. Value Creation Analysis
18.6.5.19. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
18.6.5.19.1. Target Population
18.6.5.19.2. Sales Forecast (USD Million)
18.6.5.19.3. Net Present Value (USD Million)
18.6.5.19.4. Value Creation Analysis
18.6.5.20. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
18.6.5.20.1. Target Patient Population
18.6.5.20.2. Sales Forecast (USD Million)
18.6.5.20.3. Net Present Value (USD Million)
18.6.5.20.4. Value Creation Analysis
18.6.5.21. BinD19 (Shenzhen BinDeBio)
18.6.5.21.1. Target Patient Population
18.6.5.21.2. Sales Forecast (USD Million)
18.6.5.21.3. Net Present Value (USD Million)
18.6.5.21.4. Value Creation Analysis
18.6.5.22. CARCIK-CD19 (Formula Pharmaceuticals)
18.6.5.22.1. Target Patient Population
18.6.5.22.2. Sales Forecast (USD Million)
18.6.5.22.3. Net Present Value (USD Million)
18.6.5.22.4. Value Creation Analysis
18.6.5.23. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
18.6.5.23.1. Target Patient Population
18.6.5.23.2. Sales Forecast (USD Million)
18.6.5.23.3. Net Present Value (USD Million)
18.6.5.23.4. Value Creation Analysis
18.6.5.24. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
18.6.5.24.1. Target Patient Population
18.6.5.24.2. Sales Forecast (USD Million)
18.6.5.24.3. Net Present Value (USD Million)
18.6.5.24.4. Value Creation Analysis
18.6.5.25. PBCAR269A (Precision BioSciences and Servier)
18.6.5.25.1. Target Patient Population
18.6.5.25.2. Sales Forecast (USD Million)
18.6.5.25.3. Net Present Value (USD Million)
18.6.5.25.4. Value Creation Analysis
18.6.5.26. CD123 CAR-T cellsTherapy (Chongqing Precision Biotechnology)
18.6.5.26.1. Target Patient Population
18.6.5.26.2. Sales Forecast (USD Million)
18.6.5.26.3. Net Present Value (USD Million)
18.6.5.26.4. Value Creation Analysis
18.6.5.27. BCMA CAR-T (Chongqing Precision Biotech)
18.6.5.27.1. Target Patient Population
18.6.5.27.2. Sales Forecast (USD Million)
18.6.5.27.3. Net Present Value (USD Million)
18.6.5.27.4. Value Creation Analysis
18.6.5.28. P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine)
18.6.5.28.1. Target Patient Population
18.6.5.28.2. Sales Forecast (USD Million)
18.6.5.28.3. Net Present Value (USD Million)
18.6.5.28.4. Value Creation Analysis
18.7. Overall TCR-based Therapies Market
18.7.1. TCR-Based Therapies Market: Distribution by Target Indication
18.7.2. TCR-Based Therapies Market: Distribution by Target Antigen
18.7.3. TCR-Based Therapies Market: Key Players
18.7.4. TCR-Based Therapies Market: Distribution by Geography
18.7.5. Product Wise Sales Forecast
18.7.5.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
18.7.5.1.1. Target Patient Population
18.7.5.1.2. Sales Forecast (USD Million)
18.7.5.1.3. Net Present Value (USD Million)
18.7.5.1.4. Value Creation Analysis
18.7.5.2. IMCgp100 (Immunocore)
18.7.5.2.1. Target Patient Population
18.7.5.2.2. Sales Forecast (USD Million)
18.7.5.2.3. Net Present Value (USD Million)
18.7.5.2.4. Value Creation Analysis
18.7.5.3. YT-E001 (China Immunotech)
18.7.5.3.1. Target Patient Population
18.7.5.3.2. Sales Forecast (USD Million)
18.7.5.3.3. Net Present Value (USD Million)
18.7.5.3.4. Value Creation Analysis
18.7.5.4. TBI-1301 (Takara Bio)
18.7.5.4.1. Target Patient Population
18.7.5.4.2. Sales Forecast (USD Million)
18.7.5.4.3. Net Present Value (USD Million)
18.7.5.4.4. Value Creation Analysis
18.7.5.5. ALT 801 (Altor BioScience)
18.7.5.5.1. Target Patient Population
18.7.5.5.2. Sales Forecast (USD Million)
18.7.5.5.3. Net Present Value (USD Million)
18.7.5.5.4. Value Creation Analysis
18.7.5.6. JTCR016 (Juno Therapeutics)
18.7.5.6.1. Target Patient Population
18.7.5.6.2. Sales Forecast (USD Million)
18.7.5.6.3. Net Present Value (USD Million)
18.7.5.6.4. Value Creation Analysis
18.7.5.7. LioCyx (Lion TCR)
18.7.5.7.1. Target Patient Population
18.7.5.7.2. Sales Forecast (USD Million)
18.7.5.7.3. Net Present Value (USD Million)
18.7.5.7.4. Value Creation Analysis
18.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
18.7.5.8.1. Target Patient Population
18.7.5.8.2. Sales Forecast (USD Million)
18.7.5.8.3. Net Present Value (USD Million)
18.7.5.8.4. Value Creation Analysis
18.8. Overall TIL-Based Therapies Market
18.8.1. TIL-Based Therapies Market: Distribution by Target Indication
18.8.2. TIL-Based Therapies Market: Key Players
18.8.3. TIL-Based Therapies Market: Distribution by Geography
18.8.3.1. TILs (Netherlands Cancer Institute)
18.8.3.1.1. Target Patient Population
18.8.3.1.2. Sales Forecast (USD Million)
18.8.3.1.3. Net Present Value (USD Million)
18.8.3.1.4. Value Creation Analysis
18.8.3.2. Lifileucel (LN-144) (Iovance Biotherapeutics)
18.8.3.2.1. Target Patient Population
18.8.3.2.2. Sales Forecast (USD Million)
18.8.3.2.3. Net Present Value (USD Million)
18.8.3.2.4. Value Creation Analysis
18.8.3.3. LN-145 (Iovance Biotherapeutics)
18.8.3.3.1. Target Patient Population
18.8.3.3.2. Sales Forecast (USD Million)
18.8.3.3.3. Net Present Value (USD Million)
18.8.3.3.4. Value Creation Analysis
18.8.3.4. IOV-2001 (Iovance Biotherapeutics)
18.8.3.4.1. Target Patient Population
18.8.3.4.2. Sales Forecast (USD Million)
18.8.3.4.3. Net Present Value (USD Million)
18.8.3.4.4. Value Creation Analysis
18.8.3.5. LTX-315 and TILs (Lytix Biopharma)
18.8.3.5.1. Target Patient Population
18.8.3.5.2. Sales Forecast (USD Million)
18.8.3.5.3. Net Present Value (USD Million)
18.8.3.5.4. Value Creation Analysis
18.8.3.6. Allogeneic donor lymphocyte infusions (DLI) (Amgen / University of Munich)
18.8.3.6.1. Target Patient Population
18.8.3.6.2. Sales Forecast (USD Million)
18.8.3.6.3. Net Present Value (USD Million)
18.8.3.6.4. Value Creation Analysis
18.8.3.7. TILs (CAR-T (Shanghai) Cell Biotechnology) (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary Surgery Hospital)
18.8.3.7.1. Target Patient Population
18.8.3.7.2. Sales Forecast (USD Million)
18.8.3.7.3. Net Present Value (USD Million)
18.8.3.7.4. Value Creation Analysis
19. PROMOTIONAL ANALYSIS
19.1. Chapter Overview
19.2. Channels Used for Promotional Campaigns
19.3. Summary of Product Website Analysis
19.4. Summary of Patient Support Services and Informative Downloads
19.5. Kymriah: Promotional Analysis
19.5.1. Drug Overview
19.5.2. Product Website Analysis
19.5.2.1. Messages for Healthcare Professionals
19.5.2.2. Messages for Patients
19.5.3. Patient Support Services and Informative Downloads
19.5.4. Other Promotional Activities
19.5.4.1. Presence in Conferences
19.6. Yescarta: Promotional Analysis
19.6.1. Drug Overview
19.6.2. Product Website Analysis
19.6.2.1. Messages for Healthcare Professionals
19.6.2.3. Messages for Patients
19.6.3. Patient Support Services and Informative Downloads
19.6.4. Other Promotional Activities
19.6.4.1. Presence in Conferences
20. COMPANY PROFILES
20.1. Chapter Overview
20.2. Adaptimmune Therapeutics
20.3. Autolus
20.4. bluebird bio
20.5. CARsgen Therapeutics
20.6. Celegene (A Bristol Myers Squibb Company)
20.7. Cellectis
20.8. Cellular Biomedicine Group
20.9. Cogent Biosciences
20.10. Immunocore
20.11. Innovative Cellular Therapeutics
20.12. Iovance Biotherapeutics
20.13. Kuur Therapeutics
20.14. Kite Pharma (A Gilead Sciences Company)
20.15. Lion TCR
20.16. Noile-Immune Biotech
20.17. Novartis
20.18. Shanghai GeneChem
20.19. Sinobioway Cell Therapy
20.20. Takara Bio
20.21. ZIOPHARM Oncology
21. CONCLUDING REMARKS
21.1. Chapter Overview
22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Cell Therapies
22.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer
22.3. Glycostem Therapeutics
22.3.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
22.4. Gracell Biotechnologies
22.4.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
22.5. Lion TCR
22.5.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
22.6. TxCell
22.6.1. Interview Transcript: Miguel Forte, Chief Operating Officer
22.7. Kite Pharma
22.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
22.8. Celyad
22.8.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
22.9. Iovance Biotherapeutics
22.9.1. Interview Transcript: Peter Ho, Director, Process Development
22.10. Waisman Biomanufacturing
22.10.1. Interview Transcript: Brian Dattilo, Manager of Business Development
22.11. Theravectys
22.11.1. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
22.12. Changhai Hospital
22.12.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
22.13. University of Colorado
22.13.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
23. APPENDIX 1: TABULATED DATA
24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Historical Development of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 3.11 TCR-based Therapies: Development Process
Figure 3.12 TIL-based Therapies: Development Process
Figure 3.13 T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1 Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
Figure 4.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3 Social Media Analysis: Most Popular Drug Candidates on Twitter
Figure 4.4 Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5 Average Number of Likes, Re-tweets and Comments Related to T-cell Immunotherapy
Figure 4.6 Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1 T-Cell Immunotherapies: Distribution by Type of Product
Figure 5.2 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 5.3 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 5.4 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
Figure 5.5 CAR-T Cell Therapies: Distribution by Popular Target Indications
Figure 5.6 CAR-T Cell Therapies: Distribution by Popular Target Antigens
Figure 5.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 5.8 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 5.9 CAR-T Cell Therapies: Distribution by Dose Frequency
Figure 5.10 CAR-T Cell Therapies: Distribution by Patient Segment
Figure 5.11 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 5.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.13 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.15 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 5.16 TCR-based Therapies: Distribution by Type of Developer
Figure 5.17 TCR-based Therapies: Distribution by Phase of Development
Figure 5.18 TCR-based Therapies: Distribution by Target Therapeutic Area
Figure 5.19 TCR-based Therapies: Distribution by Popular Target Indications
Figure 5.20 TCR-based Therapies: Distribution by Popular Target Antigen
Figure 5.21 TCR-based Therapies: Distribution by Source of T-Cells
Figure 5.22 TCR-based Therapies: Distribution by Route of Administration
Figure 5.23 TCR-based Therapies: Distribution by Dose Frequency
Figure 5.24 TCR-based Therapies: Distribution by Patient Segment
Figure 5.25 TCR-based Therapies: Distribution by Type of Therapy
Figure 5.26 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.27 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.28 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.29 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 5.30 TIL-based Therapies: Distribution by Type of Developer
Figure 5.31 TIL-based Therapies: Distribution by Phase of Development
Figure 5.32 TCR-based Therapies: Distribution by Target Therapeutic Area
Figure 5.33 TIL-based Therapies: Distribution by Popular Target Indications
Figure 5.34 TIL-based Therapies: Distribution by Source of T-Cells
Figure 5.35 TIL-based Therapies: Distribution by Dose Frequency
Figure 5.36 TIL-based Therapies: Distribution by Patient Segment
Figure 5.37 TIL-based Therapies: Distribution by Type of Therapy
Figure 5.38 TIL-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.39 TIL-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.40 TIL-based Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 6.1 T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
Figure 6.2 T-Cell Immunotherapies: Popular Targets in Solid Tumor
Figure 6.3 CAR-T Cell Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4 CAR-T Cell Immunotherapies: Prominent Key Opinion Leaders
Figure 6.5 TCR-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.6 TCR-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.7 TIL-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.8 TIL-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.9 CAR-Construction: Analysis by Generation of CAR-T Therapies
Figure 6.10 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Figure 6.11 CAR-Construction: Analysis by Type of Vector
Figure 6.12 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Figure 7.1 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2016-2019)
Figure 8.1 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 10.1 Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 11.1 Leukemia: Classification
Figure 11.2 Leukemia: Global Epidemiological Distribution
Figure 11.3 Lymphoma: Global Epidemiological Distribution
Figure 11.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 11.5 Melanoma: Global Epidemiological Distribution
Figure 11.6 Lung Cancers: Classification
Figure 11.7 Lung Cancer: Global Epidemiological Distribution
Figure 11.8 Pancreatic Cancer: Global Epidemiological Distribution
Figure 11.9 Liver Cancer: Global Epidemiological Distribution
Figure 11.10 Breast Cancer: Global Epidemiological Distribution
Figure 11.11 Ovarian Cancer: Global Epidemiological Distribution
Figure 11.12 Bladder Cancer: Global Epidemiological Distribution
Figure 11.13 Kidney Cancer: Global Epidemiological Distribution
Figure 12.1 Genome Editing Technologies: Applications
Figure 12.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Therapies
Figure 12.3 Competitiveness Analysis: Gene Editing Platforms
Figure 12.4 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 12.5 Cellectis: Properties of Enhanced T-Cell Platform
Figure 12.6 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 13.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Figure 13.2 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2013-2020
Figure 13.3 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
Figure 13.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 13.6 Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Figure 13.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 13.8 Partnerships and Collaborations: Distribution by Type of Player and Type of Product
Figure 13.8 Partnerships and Collaborations: Distribution by Individual Products
Figure 13.10 Partnerships and Collaborations: Most Active Industry Players
Figure 13.11 Partnerships and Collaborations: Most Active Non-Industry Players
Figure 13.12 Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 13.13 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Figure 13.14 Partnerships and Collaborations: Regional Distribution
Figure 13.15 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend of funding Instances, Pre 2013-2020 (till October)
Figure 14.2 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre 2013-2020 (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 14.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 14.5 Funding and Investments: Distribution by Amount Invested across Different Types of Therapies, Pre-2012-2020 (till October)
Figure 14.6 Most Active Players: Distribution by Number of Instances
Figure 14.7 Funding and Investments: Distribution by Types of Investor
Figure 14.8 Most Active Players: Distribution by Number of Instances
Figure 14.9 Funding and Investment Analysis: Distribution by Geography
Figure 14.10 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Figure 15.1 Other T-Cell Immunotherapies: Analysis by Phase of Development
Figure 15.2 Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Figure 15.3 Other T-Cell Immunotherapies: Analysis by Type of T-Cells
Figure 15.4 Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Figure 15.5 Treg Cells: Functions
Figure 16.1 Steps for Manufacturing Cell Therapies
Figure 16.2 Centralized Manufacturing: Process Model
Figure 16.3 Decentralized Manufacturing: Process Model
Figure 16.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 16.5 Cell Therapy: Challenges and Drivers
Figure 16.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 16.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 16.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 17.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 18.1 Overall T-Cell Immunotherapy Market, 2021-2030 (USD Billion)
Figure 18.2 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2030 (USD Million)
Figure 18.3 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Figure 18.4 T-Cell Immunotherapy Market: Distribution by Target Antigens(s), 2025 and 2030 (USD Billion)
Figure 18.5 T-Cell Immunotherapy Market: Key Players, 2025 and 2030 (USD Billion)
Figure 18.6 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 18.7 Overall CAR-T Cell Therapies Market, 2021-2030 (USD Billion)
Figure 18.8 CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.9 CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Figure 18.10 CAR-T Cell Therapies Market: Key Players (USD Billion)
Figure 18.11 CAR-T Cell Therapies Market: Distribution by Target Geography (USD Billion)
Figure 18.12 Kymriah (Novartis): Current Status of Development
Figure 18.13 Kymriah (Novartis) Sales Forecast, till 2030 (USD Million)
Figure 18.14 Yescarta (Gilead Sciences): Current Status of Development
Figure 18.15 Yescarta (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 18.16 Tecartus: Current Status of Development
Figure 18.17 Tecartus: (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 18.18 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Current Status of Development
Figure 18.19 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, till 2030 (USD Million)
Figure 18.20 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Current Status of Development
Figure 18.21 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
Figure 18.22 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
Figure 18.23 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030 (USD Million)
Figure 18.24 MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 18.25 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
Figure 18.26 Descartes-11 (Cartesian Therapeutics): Current Status of Development
Figure 18.27 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.28 CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 18.29 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
Figure 18.30 AUTO1 (Autolus): Current Status of Development
Figure 18.31 AUTO1 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.32 AUTO3 (Autolus): Current Status of Development
Figure 18.33 AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.34 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 18.35 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
Figure 18.36 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.37 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.38 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.39 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.40 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 18.41 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
Figure 18.42 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 18.43 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2030 (USD Million)
Figure 18.44 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 18.45 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.46 TBI-1501 (Takara Bio): Current Status of Development
Figure 18.47 TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.48 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current
Figure 18.49 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.50 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 18.51 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
Figure 18.52 BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 18.53 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
Figure 18.54 CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 18.55 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
Figure 18.56 EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
Figure 18.57 EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.58 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 18.59 Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.60 PBCAR269A (Precision BioSciences and Servier): Current Status of Development
Figure 18.61 PBCAR269A (Precision BioSciences and Servier) Sales Forecast, till 2030 (USD Million)
Figure 18.62 CD123 CAR-T cells (Chongqing Precision Biotechnology): Current Status of Development
Figure 18.63 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.64 BCMA CAR-T (Chongqing Precision Biotech): Current Status of Development
Figure 18.65 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, till 2030 (USD Million)
Figure 18.66 P-BCMA-101 (Poseida Therapeutics / California Institute for Regenerative Medicine): Current Status of Development
Figure 18.67 P-BCMA-101 (Poseida Therapeutics and California Institute for Regenerative Medicine) Sales Forecast, till 2030 (USD Million)
Figure 18.56 Overall TCR-based Therapies Market, 2020-2030 (USD Billion)
Figure 18.68 TCR-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.69 TCR-Based Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Figure 18.70 TCR-Based Therapies Market: Key Players (USD Billion)
Figure 18.71 TCR-Based Therapies Market: Distribution by Target Geography (USD Billion)
Figure 18.72 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Current Status of Development
Figure 18.73 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030 (USD Million)
Figure 18.74 IMCgp100 (Immunocore): Current Status of Development
Figure 18.75 IMCgp100 (Immunocore) Sales Forecast, till 2030 (USD Million)
Figure 18.76 YT-E001 (China Immunotech): Current Status of Development
Figure 18.77 YT-E001 (China Immunotech) Sales Forecast, till 2030 (USD Million)
Figure 18.78 TBI-1301 (Takara Bio): Current Status of Development
Figure 18.79 TBI-1301 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.80 ALT 801 (Altor BioScience): Current Status of Development
Figure 18.81 ALT 801 (Altor BioScience) Sales Forecast, till 2030 (USD Million)
Figure 18.82 JTCR016 (Juno Therapeutics): Current Status of Development
Figure 18.83 JTCR016 (Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.84 LioCyx (Lion TCR): Current Status of Development
Figure 18.85 LioCyx (Lion TCR) Sales Forecast, till 2030 (USD Million)
Figure 18.86 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Current Status of Development
Figure 18.87 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.88 Overall TIL-based Therapies Market, 2020-2030 (USD Billion)
Figure 18.89 TIL-Based Therapies Market: Distribution by Target Indication(s) (USD Billion)
Figure 18.90 TIL-Based Therapies Market: Key Players (USD Billion)
Figure 18.91 TIL-Based Therapies Market: Distribution by Target Geography (USD Billion)
Figure 18.92 TILs (Netherland Cancer Institute): Current Status of Development
Figure 18.93 TILs (Netherland Cancer Institute) Sales Forecast, till 2030 (USD Million)
Figure 18.94 Lifileucel (LN-144) (Iovance Biotherapeutics): Current Status of Development
Figure 18.95 Lifileucel (LN-144) Sales Forecast, till 2030 (USD Million)
Figure 18.96 LN-145 (Iovance Biotherapeutics): Current Status of Development
Figure 18.97 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.98 IOV-2001 (Iovance Biotherapeutics): Current Status of Development
Figure 18.99 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.100 LTX-315 and TILs (Lytix Biopharma): Current Status of Development
Figure 18.101 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030 (USD Million)
Figure 18.102 Allogeneic donor lymphocyte infusions (DLI) (University of Munich, Amgen): Current Status of Development
Figure 18.103 Allogeneic donor lymphocyte infusions (DLI) (University of Munich, Amgen) Sales Forecast, till 2030 (USD Million)
Figure 18.104 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary Surgery Hospital): Current Status of Development
Figure 18.105 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary Surgery Hospital) Sales Forecast, till 2030 (USD Million)
Figure 19.1 Channels Used for Promotional Campaigns
Figure 19.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 19.3 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 19.4 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 19.5 Product Website Analysis: Kymriah, Messages for Patients
Figure 19.6 Product Website Analysis: Kymriah, Patient Support Program
Figure 19.7 Kymriah, Presence in Conferences
Figure 19.8 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 19.9 Product Website Analysis: Yescarta, Messages for Patients
Figure 19.10 Product Website Analysis: Yescarta, Kite Konnect
Figure 19.11 Product Website Analysis: Yescarta, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
Figure 19.12 Yescarta, Presence in Conferences
Figure 21.1 Concluding Remarks: Overall Market Landscape
Figure 21.2 Concluding Remarks: Clinical Trial Analysis
Figure 21.3 Concluding Remarks: Partnerships & Collaborations and Funding and Investment Analysis
Figure 21.4 Concluding Remarks: Other T-cell Immunotherapies
Figure 21.5 Concluding Remarks: Market Forecast
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9 CAR-T Cell and TCR-based Therapies: Key Differences
Table 5.1 CAR-T Cell Therapies: Clinical Pipeline,
Table 5.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Patient Target Segment, Type of Therapy and Dosing Frequency
Table 5.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 5.4 TCR-based Therapies: Clinical Pipeline
Table 5.5 T CR-based Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 5.6 TCR-based Therapies: Information on Sponsor, Type of Developer, Target Antigen, Target Indication and Therapeutic Area
Table 5.7 TIL-based Therapies: Clinical Pipeline
Table 5.8 TIL-based Therapies: Preclinical Pipeline
Table 6.1 CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2 CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3 BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4 BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5 Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6 Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7 GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8 GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9 CAR-T Cell Immunotherapies: Principle Investigators
Table 6.10 TCR-based Immunotherapies: Principle Investigators
Table 6.11 TIL-based Immunotherapies: Principle Investigators
Table 6.12 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 7.1 CAR-T Cell Immunotherapies: List of Clinical Trials
Table 7.2 Advanced Phase CAR-T Cell Therapies in China
Table 8.1 Kymriah: Clinical Studies
Table 8.2 Kymriah: Clinical Trial Endpoints (ALL)
Table 8.3 Kymriah: Clinical Trial Endpoints (CLL / NHL / FL / MCL / CNSL)
Table 8.4 Yescarta: Clinical Studies
Table 8.5 Yescarta: Clinical Trial Endpoints
Table 8.6 Tecartus / Brexucabtagene Autoleucel: Clinical Studies
Table 8.7 Tecartus / Brexucabtagene Autoleucel: Clinical Trial Endpoints
Table 8.8 JCAR Series: Molecules in Clinical Development
Table 8.9 JCAR: CAR-T Design
Table 8.10 JCAR014: Clinical Studies
Table 8.11 JCAR017: Clinical Studies
Table 8.12 JCAR018: Clinical Studies
Table 8.13 JCAR020: Clinical Studies
Table 8.14 JCAR023: Clinical Studies
Table 8.15 JCAR024: Clinical Studies
Table 8.16 JCARH125: Clinical Studies
Table 8.17 JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.18 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.19 JCAR: Dosage Regimen
Table 8.20 Idecabtagene Vicleucel / bb2121: Clinical Studies
Table 8.21 Idecabtagene Vicleucel / bb2121: Clinical Trial Endpoints
Table 8.22 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Studies
Table 8.23 Ciltacabtagene Autoleucel / LCAR-B38M / JUN-68284528: Clinical Trial Endpoints
Table 8.24 TBI-1501: Clinical Studies
Table 8.25 TBI-1501: Clinical Trial Endpoints
Table 8.26 TBI-1501: Dosage Regimen
Table 8.27 AUTO1: Clinical Studies
Table 8.28 AUTO3: Clinical Studies
Table 8.29 AUTO4: Clinical Studies
Table 8.30 Autolus’s Next Generation CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.31 Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Clinical Studies
Table 8.32 Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Clinical Studies
Table 8.33 Sinobioway Cell Therapy’s Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.34 Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
Table 9.1 Letetresgene Autoleucel / GSK3377794 / NY-ESO TCR SPEAR T-Cell: Clinical Studies
Table 9.2 ADP-A2M10 (MAGE-A10) SPEAR T-Cell Therapy: Clinical Studies
Table 9.3 ADP-A2M4 (MAGE-A4) SPEAR T-Cell Therapy: Clinical Studies
Table 9.4 ADP-A2AFP SPEAR T-Cell Therapy: Clinical Studies
Table 9.5 Letetresgene Autoleucel / GSK3377794 / NY-ESO TCR SPEAR T-Cell: Clinical Trial Endpoints
Table 9.6 A2M10 / ADP-A2M4 / ADP-A2AFP: Clinical Trial Endpoints
Table 9.7 IMCgp100: Clinical Studies
Table 9.8 IMCgp100: Clinical Trial Endpoints
Table 9.9 ALT-801: Clinical Studies
Table 9.10 ALT-801: Clinical Trial Endpoints
Table 9.11 JTCR016: Clinical Studies
Table 9.12 JTCR016: Clinical Trial Endpoints
Table 9.13 WT1 TCR: Clinical Studies
Table 9.14 WT1 TCR: Clinical Trial Endpoints
Table 9.15 TBI-1301: Current Status of Development
Table 9.16 TBI-1301: Clinical Trial Endpoints
Table 9.17 MDG1011: Clinical Studies
Table 9.18 MDC1011: Clinical Trial Endpoints
Table 9.19 Phase I/II or Phase II TCR-based Cell Therapies from the Industry Players
Table 10.1 LN-144: Clinical Studies
Table 10.2 LN-144: Clinical Trial Endpoints
Table 10.3 LN-145: Current Status of Development
Table 10.4 LN-145: Clinical Trial Endpoints
Table 10.5 LN-144: Patent Portfolio
Table 10.6 Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 10.7 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 10.8 Phase I/II or Phase II TIL-based Cell Therapies from the Industry Players
Table 11.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 11.2 Leukemia: List of Marketed Targeted Therapeutics,
Table 11.3 Lymphoma: List of Marketed Targeted Therapeutics,
Table 11.4 T-Cell Immunotherapies: Targets under Investigation for Leukemia
Table 11.5 T-Cell Immunotherapies: Targets under Investigation for Lymphoma
Table 11.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 11.7 T-Cell Immunotherapies: Targets under Investigation for Multiple Myeloma
Table 11.8 Melanoma: List of Marketed Targeted Therapeutics,
Table 11.9 TIL Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
Table 11.10 T-Cell Immunotherapies: TIL Therapies under Investigation for Metastatic Melanoma
Table 11.11 Lung Cancer: List of Marketed Targeted Therapeutics,
Table 11.12 T-Cell Immunotherapies: Targets under Investigation for Lung Cancer
Table 11.13 Pancreatic Cancer: List of Marketed Targeted Therapeutics,
Table 11.14 T-Cell Immunotherapies: Targets under Investigation for Pancreatic Cancer
Table 11.15 Liver Cancer: List of Marketed Targeted Therapeutics,
Table 11.16 CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
Table 11.17 TCR-based Therapies: Targets under Investigation for Liver Cancer
Table 11.18 Breast Cancer: List of Marketed Targeted Therapeutics,
Table 11.19 CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
Table 11.20 TCR-based Therapies: Targets under Investigation for Breast Cancer
Table 11.21 Ovarian Cancer: List of Marketed Targeted Therapeutics,
Table 11.22 T-Cell Immunotherapies: Targets under Investigation for Ovarian Cancer
Table 11.23 Bladder Cancer: List of Marketed Targeted Therapeutics,
Table 11.24 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics,
Table 12.1 Editas Medicine: CRISPR / Cas9 Technology, Research Publications,
Table 12.2 Editas Medicine: Funding Instances
Table 12.3 Editas Medicine: Collaborations
Table 12.4 Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 12.5 Intellia Therapeutics: Funding Instances
Table 11.6 Intellia Therapeutics: Collaborations
Table 11.7 CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
Table 12.8 CRISPR Therapeutics: Funding Instances
Table 12.9 CRISPR Therapeutics: Collaborations
Table 12.10 Beam Therapeutics: Funding Instances
Table 12.11 Beam Therapeutics: Collaborations
Table 12.12 Gracell Biotechnologies: Funding Instances
Table 12.13 Cellectis: Funding Instances
Table 12.14 Cellectis: Collaborations
Table 12.15 bluebird bio: megaTAL Technology, Research Publications
Table 12.16 bluebird bio: Funding Instances
Table 12.17 bluebird bio: Collaborations
Table 12.18 Sangamo Therapeutics: Funding Instances
Table 12.19 Sangamo Therapeutics: Collaborations
Table 12.20 Cogent Biosciences: Funding Instances
Table 12.21 Cogent Biosciences: Collaborations
Table 12.22 Celyad: Funding Instances
Table 12.23 Celyad: Collaborations
Table 12.24 Glycostem: Funding Instances
Table 12.25 Glycostem: Collaborations
Table 12.26 Intrexon: Funding Instances
Table 12.27 Intrexon: Collaborations
Table 12.28 Bellicum Pharmaceuticals: Key Switch Technologies
Table 12.29 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 12.30 Bellicum Pharmaceuticals: Funding Instances
Table 12.31 Bellicum Pharmaceuticals: Collaborations
Table 12.32 Theravectys: Funding Instances
Table 12.33 Technologies For CAR-T Safety Enhancement
Table 12.34 Formula Pharmaceuticals: Collaborations
Table 13.1 T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2005-2020 (till October)
Table 14.1 T-Cell Immunotherapies: Funding and Investments, 2000-2020 (till October)
Table 14.2 T-Cell Immunotherapies: Summary of Investments
Table 15.1 List of Other Novel T-Cell Immunotherapies
Table 15.2 Treg Cells: Properties
Table 16.1 Assessment Strategies for Different Manufacturing Processes
Table 16.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 16.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 17.1 Price of Marketed Gene / Cell Therapies
Table 17.2 Price of Marketed Targeted Drugs
Table 17.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 17.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 18.1 T-Cell Immunotherapies: List of Forecasted Molecules
Table 18.2 Kymriah (Novartis): Net Present Value (USD Million)
Table 18.3 Kymriah (Novartis): Value Creation Analysis (USD Million)
Table 18.4 Yescarta (Gilead Sciences): Net Present Value (USD Million)
Table 18.5 Yescarta (Gilead Sciences): Value Creation Analysis (USD Million)
Table 18.6 Tecartus: (Gilead Sciences): Net Present Value (USD Million)
Table 18.7 Tecartus: (Gilead Sciences): Value Creation Analysis (USD Million)
Table 18.8 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Net Present Value (USD Million)
Table 18.9 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 18.10 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Net Present Value (USD Million)
Table 18.11 Ciltacabtagene Autoleucel / LCAR-B38M (Nanjing Legend Biotech /Janssen): Value Creation Analysis (USD Million)
Table 18.12 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Net Present Value (USD Million)
Table 18.13 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Value Creation Analysis (USD Million)
Table 18.14 MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
Table 18.15 MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
Table 18.16 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 18.17 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 18.18 CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
Table 18.19 CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
Table 18.20 AUTO1 (Autolus): Net Present Value (USD Million)
Table 18.21 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 18.22 AUTO3 (Autolus): Net Present Value (USD Million)
Table 18.23 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 18.24 GPC3 CAR-T (Shanghai GeneChem): Net Present Value (USD Million)
Table 18.25 GPC3 CAR-T (Shanghai GeneChem): Value Creation Analysis (USD Million)
Table 18.26 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 18.27 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 18.28 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 18.29 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 18.30 CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
Table 18.31 CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
Table 18.32 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 18.33 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 18.34 PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 18.35 PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 18.36 TBI-1501 (Takara Bio): Net Present Value (USD Million)
Table 18.37 TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
Table 18.38 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 18.39 IM19 CAR-T T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 18.40 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 18.41 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 18.42 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 18.43 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 18.44 CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
Table 18.45 CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 18.46 EGFR CART (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
Table 18.47 EGFR CART (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
Table 18.48 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 18.49 ANTI-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 18.50 PBCAR269A (Precision BioSciences and Servier): Net Present Value (USD Million)
Table 18.51 PBCAR269A (Precision BioSciences and Servier): Value Creation Analysis (USD Million)
Table 18.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 18.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 18.54 BCMA CAR-T (Chongqing Precision Biotech): Net Present Value (USD Million)
Table 18.55 BCMA CAR-T (Chongqing Precision Biotech): Value Creation Analysis (USD Million)
Table 18.56 P-BCMA-101 (Poseida Therapeutics / California Institute for Regenerative Medicine): Net Present Value (USD Million)
Table 18.57 P-BCMA-101 (Poseida Therapeutics / California Institute for Regenerative Medicine): Value Creation Analysis (USD Million)
Table 18.58 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Net Present Value (USD Million)
Table 18.59 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Value Creation Analysis (USD Million)
Table 18.60 IMCgp100 (Immunocore): Net Present Value (USD Million)
Table 18.61 IMCgp100 (Immunocore): Value Creation Analysis (USD Million)
Table 18.62 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 18.63 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 18.64 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 18.65 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 18.66 ALT 801 (Altor BioScience): Net Present Value (USD Million)
Table 18.67 ALT 801 (Altor BioScience): Value Creation Analysis (USD Million)
Table 18.68 JTCR016 (Juno Therapeutics): Net Present Value (USD Million)
Table 18.69 JTCR016 (Juno Therapeutics): Value Creation Analysis (USD Million)
Table 18.70 LioCyx (Lion TCR): Net Present Value (USD Million)
Table 18.71 LioCyx (Lion TCR): Value Creation Analysis (USD Million)
Table 18.72 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 18.73 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 18.74 TILs (Netherland Cancer Institute): Net Present Value (USD Million)
Table 18.75 TILs (Netherland Cancer Institute): Value Creation Analysis (USD Million)
Table 18.76 Lifileucel (LN-144) (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.77 TILs (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 18.78 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.79 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 18.80 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 18.81 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 18.82 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 18.83 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 18.84 Allogeneic Donor Lymphocyte Infusions (DLI) (Amgen / University of Munich): Net Present Value (USD Million)
Table 18.85 Allogeneic Donor Lymphocyte Infusions (DLI) (Amgen / University of Munich: Value Creation Analysis (USD Million)
Table 18.86 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary Surgery Hospital): Net Present Value (USD Million)
Table 18.87 TILs (CAR-T (Shanghai) Cell Biotechnology / Eastern Hepatobiliary Surgery Hospital): Value Creation Analysis (USD Million)
Table 19.1 Kymriah: Drug Overview
Table 19.2 Yescarta: Drug Overview
Table 20.1 Adaptimmune Therapeutics: Company Profile
Table 20.2 Autolus: Company Profile
Table 20.3 bluebird bio: Company Profile
Table 20.4 CARsgen Therapeutics: Company Profile
Table 20.5 Celgene: Company Profile
Table 20.6 Cellectis: Company Profile
Table 20.7 Cellular Biomedicine Group: Company Profile
Table 20.8 Cogent Biosciences: Company Profile
Table 20.9 Immunocore: Company Profile
Table 20.10 Innovative Cellular Therapeutics: Company Profile
Table 20.11 Iovance Biotherapeutics: Company Profile
Table 20.12 Kuur Therapeutics: Company Profile
Table 20.13 Kite Pharma: Company Profile
Table 20.14 Lion TCR: Company Profile
Table 20.15 Noile-Immune Biotech: Company Profile
Table 20.16 Novartis: Company Profile
Table 20.17 Shanghai Genechem: Company Profile
Table 20.18 Sinobioway Cell Therapy: Company Profile
Table 20.19 Takara Bio: Company Profile
Table 20.20 ZIOPHARM Oncology: Company Profile
Table 23.1 T-Cell Immunotherapies: Distribution by Type of Product
Table 23.2 CAR-T Cell Therapies: Distribution by Type of Developer
Table 23.3 CAR-T Cell Therapies: Distribution by Phase of Development
Table 23.4 CAR-T Cell Therapies: Distribution by Target Therapeutic Area
Table 23.5 CAR-T Cell Therapies: Distribution by Popular Target Indications
Table 23.6 CAR-T Cell Therapies: Distribution by Popular Target Antigen
Table 23.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 23.8 CAR-T Cell Therapies: Distribution by Route of Administration
Table 23.9 CAR-T Cell Therapies: Distribution by Dose Frequency
Table 23.10 CAR-T Cell Therapies: Distribution by Patient Segment
Table 23.11 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 23.12 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 23.13 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 23.14 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 23.15 CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 23.16 TCR-based Therapies: Distribution by Type of Developer
Table 23.17 TCR-based Therapies: Distribution by Phase of Development
Table 23.18 TCR-based Therapies: Distribution by Target Therapeutic Area
Table 23.19 TCR-based Therapies: Distribution by Popular Target Indications
Table 23.20 TCR-based Therapies: Distribution by Popular Target Antigen
Table 23.21 TCR-based Therapies: Distribution by Source of T-Cells
Table 23.22 TCR-based Therapies: Distribution by Route of Administration
Table 23.23 TCR-based Therapies: Distribution by Dose Frequency
Table 23.24 TCR-based Therapies: Distribution by Patient Segment
Table 23.25 TCR-based Therapies: Distribution by Type of Therapy
Table 23.26 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 23.27 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 23.28 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 23.29 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 23.30 TIL-based Therapies: Distribution by Type of Developer
Table 23.31 TIL-based Therapies: Distribution by Phase of Development
Table 23.32 TIL-based Therapies: Distribution by Target Therapeutic Area
Table 23.33 TIL-based Therapies: Distribution by Popular Target Indications
Table 23.34 TIL-based Therapies: Distribution by Source of T-Cells
Table 23.35 TIL-based Therapies: Distribution by Dose Frequency
Table 23.36 TIL-based Therapies: Distribution by Patient Segment
Table 23.37 TIL-based Therapies: Distribution by Type of Therapy
Table 23.38 TIL-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 23.39 TIL-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 23.40 TIL-based Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 23.41 CAR-Construction: Analysis by Generation of CAR-T Therapies
Table 23.42 CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Table 23.43 CAR-Construction: Analysis by Type of Vector
Table 23.44 CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Table 23.45 CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 23.46 CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Table 23.47 Partnerships and Collaborations: Cumulative Trend Year-Wise Trend, 2005-2020
Table 23.49 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.50 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2020
Table 23.51 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 23.52 Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Table 23.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 23.54 Partnerships and Collaborations: Distribution by Type of Player and Type of Product
Table 23.55 Partnerships and Collaborations: Distribution by Individual Products
Table 23.56 Partnerships and Collaborations: Most Active Industry Players
Table 23.57 Partnerships and Collaborations: Most Active Non-Industry Players
Table 23.58 Partnerships and Collaborations: Most Active Contract Manufacturers
Table 23.59 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Table 23.60 Partnerships and Collaborations: Regional Distribution
Table 23.61 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.64 Funding and Investment Analysis: Cumulative Year-wise Trend of funding Instances, Pre 2013-2020 (Till October)
Table 23.62 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre 2013-2020 (USD Million)
Table 23.63 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 23.64 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 23.65 Funding and Investments: Distribution by Amount Invested across Different Types of Therapies, Pre-2012-2020 (till October)
Table 23.66 Most Active Players: Distribution by Number of Instances
Table 23.67 Funding and Investments: Distribution by Types of Investor
Table 23.68 Most Active Players: Distribution by Number of Instances
Table 23.69 Funding and Investment Analysis: Distribution by Geography
Table 23.70 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Table 23.71 Other T-Cell Immunotherapies: Analysis by Phase of Development
Table 23.72 Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Table 23.73 Other T-Cell Immunotherapies: Analysis by Type of Cells
Table 23.74 Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 23.75 Overall T-Cell Immunotherapy Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 23.76 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Table 23.77 T-Cell Immunotherapy Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Table 23.78 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.79 T-Cell Immunotherapy Market: Key Players, 2025 and 2030 (USD Billion)
Table 23.80 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.81 Overall CAR-T Cell Therapies Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 23.82 CAR-T Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.83 CAR-T Cell Therapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Table 23.84 CAR-T Cell Therapies Market: Key Players, 2025 and 2030 (USD Billion)
Table 23.85 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.86 Kymriah (Novartis) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.87 Yescarta (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.88 Tecartus (Gilead Sciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.89 Idecabtagene Vicleucel / bb2121 (bluebird bio / Bristol Myers Squibb) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.90 Ciltacabtagene Autoleucel / LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.91 JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.92 MB-CART19.1 (Miltenyi Biotec) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.93 Descartes-11 (Cartesian Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.94 CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.95 AUTO1 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.96 AUTO3 (Autolus) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.97 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.98 BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.99 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.100 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.101 Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.102 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.103 TBI-1501 (Takara Bio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.104 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.105 CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.106 BinD19 (Shenzhen BinDeBio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.107 CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.108 EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.109 Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.110 PBCAR269A (Precision BioSciences) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.111 CD123 CAR-T Cells (Chongqing Precision Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.112 BCMA CAR-T (Chongqing Precision Biotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.113 P-BCMA-101 (Poseida Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.114 Overall TCR-based Therapies Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 23.115 TCR-based Therapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.116 TCR-based Therapies Market: Distribution by Target Antigens(s), 2025 and 2030 (USD Billion)
Table 23.117 TCR-based Therapies Market: Key Players, 2025 and 2030 (USD Billion)
Table 23.118 TCR-based Therapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.119 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030: (USD Million)
Table 23.120 IMCgp100 (Immunocore) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.121 YT-E001 (China Immunotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.122 TBI-1301 (Takara Bio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.123 ALT-801 (Altor Bioscience) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.124 JTCR016 (Juno Therapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.125 LioCyx (Lion TCR) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.126 LMBP2-specific TCR-T (TCR CURE Biopharma Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.127 Overall TIL-Based Cell Therapies Market, 2020-2030 Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Table 23.128 TIL-Based Cell Therapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.129 TIL-Based Cell Therapies Market: Key Players, 2025 and 2030 (USD Billion)
Table 23.130 TIL-Based Cell Therapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.131 TILs (The Netherlands Cancer Institute) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.132 Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.133 LN-145 (Iovance Biotherapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.134 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.135 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.136 Allogeneic Donor Lymphocyte Infusions (DLI) (Amgen) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 23.137 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
Discounts available for multiple report purchases
sales@rootsanalysis.com